Market Overview

UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight; Overhang Removed

Share:
Related ALNY
Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump
Alnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold
The Vetr community has upgraded $ALNY to 4.5-Stars. (Vetr)

Piper Jaffray raised its rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and increased its price target from $19 to $25.

Piper Jaffray noted, "With the Tekmira litigation behind them, Alnylam can now focus on RNAi clinical progress and partnerships in 2013. Specifically, we look forward to Phase II ALN-TTR02 data this summer to prepare the company for pivotal studies by year-end. We also expect Alnylam to file INDs on sub-cutaneous formulations of ALN-TTR02 and ALN-AT3, an innovative hemophilia therapy. We also look for Alnylam to continue to partner its RNAi therapeutic pipeline, most importantly ALN-PCS to lower cholesterol."

Alnylam Pharmaceuticals closed at $17.99 on Tuesday.

Latest Ratings for ALNY

DateFirmActionFromTo
Feb 2017Ladenburg ThalmannInitiates Coverage OnBuy
Oct 2016Morgan StanleyDowngradesOverweightEqual-weight
Oct 2016BarclaysDowngradesOverweightEqual-weight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!